The emerging role of photodynamic therapy in the management of Barrett's oesophagus

Scandinavian Journal of Gastroenterology

Volumn 33, Issue 11, 1998, Pages 1121-1129

  Kubba, A K ^a,b   Krasner, N ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b c/o 1/R ^*  (United Kingdom)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BENZOPORPHYRIN DERIVATIVE; HEMATOPORPHYRIN DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ALUMINUM; PHTHALOCYANINE ZINC; PROTON PUMP INHIBITOR; TALAPORFIN;

ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; COST EFFECTIVENESS ANALYSIS; EDEMA; EPITHELIUM DYSPLASIA; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; HEART ATRIUM FIBRILLATION; HUMAN; LASER SURGERY; MINIMALLY INVASIVE SURGERY; NAUSEA; NEODYMIUM LASER; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 0031797755     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365529850172449     Document Type: Review

References (133)

1. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar lined Barrett's oesophagus. Comparison of population based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the oesophagus and gastric cardia. JAMA 1991;265:1287-9.
3. Haggitt RC. Adenocarcinoma in Barrett's oesophagus: a new epidemic? Hum Pathol 1992;23:475-6.
4. Altorki NK, Skinner DB. Adenocarcinoma in Barrett's oesophagus. Semin Surg Oncol 1990;6:274-8.
5. Streitz JM, Ellis FH, Gibb SP, Balogh K, Watkins E. Adenocarcinoma in Barrett's oesophagus: a clinipathological study of 65 cases. Ann Surg 1991;213:122-5.
6. Polepalle SC, McCallum RW. Barrett's oesophagus: current assessment and future perspectives. Gastroenterol Clin North Am 1990;90:733-44.
7. Cameron A, Ott B, Payne W. The incidence of adenocarcinoma in columnar lined (Barrett's) oesophagus. N Engl J Med 1985;313:857-9.
8. Hameeteman W, Tytgat GN, Houthoff HJ, Van den Tweel JG. Barrett's oesophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
9. Burke AP, Sobin LH, Shekitka KM, Helwig EB. Dysplasia of the stomach and Barrett's oesophagus: a follow up study. Mod Pathol 1991;4:336-41.
10. Barrett N. Chronic peptic ulcer of the oesophagus and oesophagitis. Br J Surg 1950;38:175-82.
11. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1987;315:362-71.
12. Hamilton SR, Smith RRL. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's oesophagus. Am J Clin Pathol 1987;87:301.
13. Reid BJ. Barrett's oesophagus and oesophageal adenocarcinoma. Gastroenterol Clin North Am 1991;20:817-34.
14. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch WW, Reid BJ. An endoscopie biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's oesophagus. Gastroenterology 1993;105:40-50.
15. Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high-grade dysplasia in Barrett's oesophagus. Am J Gastroenterol 1993;88:1832-6.
16. Wright TA, Gray MR, Morris AI, Gilmore IT, Ellis A, Smart HL, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996;39:574-9.
17. Van der Burgh A, Dees J, Hop WC, Van Blankstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
18. Pasha TM, Song M, Wang KK. Cost effectiveness of photodynamic therapy for high grade dysplasia in patients with Barrett's oesophagus. Gastroenterology 1997;112:110.
19. Sampliner RE, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on the extent of Barrett's oesophagus. Dig Dis Sci 1990;35:93-6.
20. Humphries T. Effect of long term medical treatment with cimetidine and bethanechol in patients with oesophagitis and Barrett's oesophagus. J Clin Gastroenterol 1987;9:28-32.
21. Collen MJ, Strong RM. Comparison of omeprazole and ranitidine in treatment of refractory gastro-oesophageal reflux disease in patients with gastric acid hypersecretion. Dig Dis Sci 1992;37:897-903.
22. Deviere J, Buset M, Dumonceau JM, Rickaert F, Cremer M. Regression of Barrett's epithelium with omeprazole. N Engl J Med 1989;320:1497-8.
23. Howden CW, Hornung CA. Do proton pump inhibitors induce regression of Barrett's oesophagus? A systemic review. Gastroenterology 1997;112:A152.
24. McDonald ML, Trastek VF, Allen MS, Deschamps C, Pairolero PC, Pairolero PC. Barrett's oesophagus: does an antireflux procedure reduce the need for endoscopic surveillance. J Thorac Cardiovasc Surg 1996;111:1135-8.
25. Sampliner RE, Fass R. Partial regression of Barrett's oesophagus - an inadequate end point. Am J Gastroenterol 1993;88: 2092-4.
26. Luman W, Lessells AM, Palmer KR. Failure of Nd-YAG photocoagulation therapy as treatment for Barrett's oesophagus: a pilot study. Eur J Gastroenterol Hepatol 1996;8:619-21.
27. Brandt LJ, Kauvar DR. Laser induced transient regression of Barrett's epithelium. Gastrointest Endosc 1992;38:619-22.
28. Sampliner RE, Hixson LJ, Fennerty B, Garewal HS. Regression of Barrett's oesophagus by laser ablation in an an acid environment. Dig Dis Sci 1993;38:365-8.
29. Salo JA, Nemlander A, Farkkila M, Kiviluoto E. Treatment of Barrett's metaplasia by antireflux surgery and endoscopie laser ablation: clinical experience in ten patients. Gastroenterology 1995;108:A1243.
30. Van Laethem L, Daviere J, Peny MO, Delhaye M, Cremer M. Complete eradication of Barrett's mucosa using Argon beam coagulation combined with omeprazole. Gastrointest Endosc 1997;45:245.
31. Sessler MJ, Becker HD, Flesch I, Grund KE. Therapeutic effect of argon plasma coagulation on small malignant gastrointestinal tumours. J Cancer Res Clin Oncol 1995;121:235-8.
32. Barr H, Shepherd NA, Dix A, Roberts DJH, Tan WC, Krasner N. Eradication of high grade dysplasia in columnar lined Barrett's oesophagus by photodynamic therapy with endogenousely generated protoporphyrin. IX. Lancet 1996;348:584-5.
33. Patrice T, Foultier MT, Yactayo S, Adam F, Galmiche JP, Douet MC, et al. Endoscopic PDT with haematoporphyrin derivative for primary treatment of gastrointestinal neoplasm in inoperable patients. Dig Dis Sci 1990;35:545-52.
34. Overholt B, Panjehpour M, Tefftellar E, Rose M. PDT for treatment of early adenocarcinoma in Barrett's oesophagus. Gastrointest Endosc 1993;39:73-6.
35. Daniel MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg 1991;61:340-8.
36. Jesionek A, Von Tappeiner H. Zur behandlung der Hautcarcinome mit fluorescienden Stoffen. Arch Klin Med 1905;82:223-7.
37. Lipson RL, Blades EJ. The photodynamic properties of a particular haematoporphyrin-derivative. Arch Dermatol 1960: 82:508-16.
38. Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR, Boyle DG. Photoradiation therapy: cure of animal tumours with haematoporphyrin and light. J Natl Cancer Inst 1975;55:115-21.
39. Raab GH, Schneilder AF, Eirmann W. Response of human endometrium and ovarian carcinoma cell lines to photodynamic therapy. Arch Gynaecol Obstet 1890;248:13-20.
40. Foote CS. Mechanisms of photosensitized oxidation. Science 1968;162:963-7.
41. Robinson RS, Roberts AJ, Campbell ID. Photo oxidation on b-hydrobutyrate dehydrogenase: studies on membrane fragments and intact mitochondria. Photochem Photobiol 1987;45:231-4.
42. Song SZ, Li JH, Zou J. Hematoporphyrin derivative and laser photodynamical reaction in the diagnosis and treatment of malignant tumours. Lasers Surg Med 1985;5:61-6.
43. Rosenberg SJ, Williams RD. Photodynamic therapy of bladder carcinoma. Urol Clin North Am 1986;13:435-44.
44. Chopp M, Derski MO, Madigan L, Jiang F, Logie B. Sensitivity of 9L gliosarcomas to photodynamic therapy. Radiat Res 1996;146:461-5.
45. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5ALA for superficial primary and secondary skin cancer. Br J Cancer 1994;69:605-8.
46. Schmidt S, Wagner U, Oehr P, Krebs D. Clinical use of photodynamic therapy in gynaecological tumour. Zentrabl Gynakol 1992;114:307-11.
47. Tromberg BJ, Svaasand LO, Fehr MK, Madsen SJ, Wyss P, Sansone B, et al. A mathematical model for light dosemetry in photodynamic destruction of human endometrium. Phys Med-Biol 1996;41:223-37.
48. Nyamekye I, Buonaccorsi G, McEwan J, MacRobert A, Bown S, Bishop C. Inhibition of intimai hyperplasia in balloon injured arteries with adjunctive phthalocyanine sensitized photodynamic therapy. Eur J Vasc Endovasc Surg 1996;11: 19-28.
49. Balchum OJ, Doiron DR, Huth GC. HpD photodynamic therapy for obstructing lung cancer. Prog Clin Biol Res 1984; 170:727-45.
50. Fan KF, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ, Bown SG. Photodynamic therapy using 5-ALA for premalignant and malignant lesions of the oral cavity. Cancer 1996;78:1374-83.
51. Wilson JHP, Van Hillegersberg R, Van den Berg JWO, Kort WJ, Terpstra OT. Photodynamic therapy for gastrointestinal tumours. Scand J Gastroenterol 1991;26 Suppl 188:20-5.
52. Ramington C. Prophyrin and haem biosynthesis and its control. Acta Med Scand 1966;445:11-24.
53. Sima AAF, Kennedy JC, Balkeslee D, Robertson DM. Experimental porphyric neuropathy: a prelimanary report. Can J Neurol Sci 1981;9:105-14.
54. Chan WS, Brasseur N, La Madeleine C, Van Lier JE. Evidence for different mechanisms of EMT-6 tumour necrosis by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin: tumour cell survival and blood flow. Anticancer Res 1996;16:1887-92.
55. Tan WC, Krasner N, O'Toole P, Lombard M. Enhancement of photodynamic therapy in gastric cancer cells by removal of iron. Gut 1997;41:14-8.
56. Potter WR, Mang TS, Dougherty TJ. The theory of photodynamic dosimetry: consequences of photodestruction of sensitizer. Photochem Photobiol 1987;46:97-101.
57. Loh CS, MacRobert AJ, Buonaccorsi G, Krasner N, Bown SG. Mucosal ablation using PDT for the treatment of dysplasia: an experimental study in the normal rat stomach. Gut 1996;38:71-8.
58. Loh CS, Bedwell J, MacRobert AJ, Krasner N, Phillips D, Bown SG. Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phthalocyanine and 5-aminolaevulinic acid. Br J Cancer 1992;66: 452-62.
59. Fromm D, Kessel D, Webber J. Feasibility of photodynamic therapy using endogenous photosensitization for colon cancer. Arch Surg 1996;131:667-9.
60. Bedwell J, MacRobert AJ, Phillips D, Bown SG. Distribution and photodynamic effect of ALA-induced PPIX in DMH rat colonie tumour model. Br J Cancer 1992;65:818.
61. DaCosta RS, Saldi R, Ter H, Lilge L, Kost J, Cirocco M, et al. Confocal fluorescence microscopy of 5-ALA induced protoporphyrin IX in human squamous and Barrett's oesophagus. Gastroenterology 1998;114:G2389.
62. Saidi R, Ter H, Lilge L, Da Costa R, Cirocco M, Kost J, et al. Tissue pharmacokinetics of ALA induced PpIX in Barrett's and squamous oesophagus. Gastroenterology 1998;114:G1124.
63. Berlin NI, Neuberger A, Scott JJ. Metabolism of 5 aminolaevulinic acid; normal pathways, studied with the aid of 15N. Biochem J 1956;64:80-90.
64. Mlkvy P, Messmann H, Regula J, Conio M, Pauer M, Millson CE, et al. Sensitization and photodynamic therapy (PDT) of gastrointestinal tumours with 5-aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX). A pilot study. Neoplasma 1995;42:3.
65. Mustajoki P, Timonen K, Gorchein A, Seppalainen E, Tenhunen J. Sustained high plasma 5 aminolaevulinic acid concentration in a volunteer: no porphyric symptoms. Eur J Clin Invest 1992;22:407.
66. Fiedler DM, Eckl PM, Krammer B. Does 5-aminolaevulinic acid induce genotoxic effects? J Photochem Photobiol Biol 1996;33:39-44.
67. Batlle AM. Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol 1993;20:5-22.
68. Nelson JS, Liaw LH, Orenstein A, Roberts WG, Berns MW. Mechanism of tumour destruction following photodynamic therapy with hematoporphyrin derivative, chlorin and phthalocyanine. J Natl Cancer Inst 1988;80:1599-605.
69. Byrne CJ, Marshallsay LV, Ward AD. The composition of photophyrin. J Photochem Photobiol 1990;6:13-27.
70. Razum N, Balchum OJ, Profio AE, Carstens F. Skin photosensitivity: duration and intensity following intravenous haematoporphyrin derivative, HpD and DHE. Photochem Photobiol 1987;46:925-8.
71. Wooten RS, Ahlquist DA, Anderson RE, Carpenter HA, Pemberton JH, Cortese DA, et al. Localisation of haematoporphyrin derivative to human colorectal cancer. Cancer 1989;64:1569-76.
72. Garza OT, Abati A, Sindelar WF, Pass HH, Hijazi WM. Cytological changes of PDT in body fluids. Diagn Cytopathol 1996;14:356-61.
73. Gibson SL, Murand RS, Chazen MD, Kelly HE, Hilf R. In vitro sensitization of tumour cell enzymes by photofrin II administered in vivo. Br J Cancer 1989;59:47-53.
74. Hayata Y, Kato H, Okitsu H, Kawaguchi M, Konaka C. Photodynamic therapy with hematoporphyrin derivative in cancer in the upper gastrointestinal tract. Semin Surg Oncol 1985;1:1-11.
75. Messnann H, Baumler W, Debl K, Abels C, Szeimies RM, Scholmerich J, et al. Indocyanine green: a new photosensitizer for PDT in human colon carcinoma cells? Intracellular uptake and phototoxic effects. Gastroenterology 1997;112:A614.
76. Messnann H, Baumler W, Debl K, Szeimies RM, Scholmerich J, Holstege A. Phototherapy of colon, hepatoma and differently graded pancreatic carcinoma cell lies after sensitization with indocyanine green. Gastroenterology 1997; 112:A614.
77. Henderson BW, Donovan JM. Release of prostaglandin E2 from cells by photodynamic treatment in vitro. Cancer Res 1989;49:6896-900.
78. Wieman TJ, Fingar VH. Photodynamic therapy. Surg Clin North Am 1992;72:609-22.
79. Van Geel IPJV, Oppelaar H, Rijken PFJW. Vascular perfusion and hypoxic areas in RIF-I tumours after photodynamic therapy. Br J Cancer 1996;73:288-93.
80. Chapman JD, McPhee MS, Walz N, Chetner MP, Stobbe CC, Soderlind K, et al. Nuclear magnetic resonance spectroscopy and sensitizer adduct measurements of photodynamic therapy induce ischaemia in solid tumours. J Natl Cancer Inst 1991;22:1650-9.
81. Chatlani PT, Bedwell J, MacRobert AJ, Barr H, Boulos PB, Krasner N, et al. Comparison of distribution of photodynamic effects of di- and tetra-sulphonated aluminium phthalocyanines in normal rat colon. Photochem Photobiol 1991;53:745-51.
82. Overholt BF, Panjehpour M, DeNova RC, Peterson MG, Jenkins C. Balloon photodynamic therapy of esophageal cancer: effect of increasing balloon size. Lasers Surg Med 1996;18:248-52.
83. Mitchell JB, McPhearson S, DeGraff W, Gamson J, Zabell A, Russo A. Oxygen dependence of hematoporphyrin derivative induced photoinactivation of Chinese hamster cells. Cancer Res 1985;45:2008-11.
84. Moan J, Sommer S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK-3025 cells. Cancer Res 1985;45:1608-10.
85. Nseyo UO, Whalen RK, Duncan MR, Berman B, Lundahl SL. Urinary cytokines following photodynamic therapy for bladder cancer. A preliminary report. Urology 1990;36:167-71.
86. Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI. Effect of photodynamic therapy on tumour necrosis factor production by murine macrophages. J Natl Cancer Inst 1990; 82:34-9.
87. Korblik M. Low density lipoprotein receptor pathway in the delivery of photofrin. How much is it relevant for selective accumalation of the photosensitizer in tumours?. J Photochem Photobiol 1992;12:107-9.
88. Hamblin MR, Newman EL. On the mechanism of tumour localising effect in photodynamic therapy. J Photochem Photobiol 1994;23:3-8.
89. Korbelik M, Krosl G, Chaplin DJ. Photofrin uptake by murine macrophages. Cancer Res 1991;51:2251-5.
90. Jori G, Beltrami M, Reddi E, Salvato B, Pagnan A, Ziron L, et al. Evidence for a major role of plasma lipoproteins as haematoporphyrin carriers in vivo. Cancer Lett 1984;24:291-7.
91. Allison BA, Waterfield E, Richter AM, Levy JG. The effects of plasma lipoprolein on in-vitro tumour cell killing and in vivo tumour photosensitization with benzoporphyrin derivative. Photochem Photobiol 1991;54:709-14.
92. Whitehurst C, Byrne K, Moore JV. Development of an alternative light source to lasers for photodynamic therapy. Lasers Med Sci 1993;8:259-67.
93. Kirschner RA, Linger M, Imber P. An introduction to dye lasers and photoradiation therapy. Surg Clin N Am 1984;64: 939-40.
94. Szeimies RM, Hein R, Baumler W, Heine A, Landthaler M. A possible new incoherent lamp for photodynamic treatment of superficial skin lesions. Acta Derm Venereol 1994;74: 117-9.
95. Veenhuizen RB, Marijnissen JPA, Kenemans P, Ruevekamp-Helmers MC, Mannetje LWV, Helmerhorst TJM, et al. Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Br J Cancer 1996;73:1387-92.
96. Kashtan H, Haddad R, Yossiphov Y, Bar-On S, Skornick Y. Photodynamic therapy of colorectal cancer using a new light source: from in vitro studies to a patient treatment. Dis Colon Rectum 1996;39:379-83.
97. Dougherty TJ, Marcus SL. Photodynamic therapy. Eur J Cancer 1992;28A:1734-42.
98. Gossner L, Sroka R, Hahn EG, Ell C. Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid. Gastrointest Endosc 1995;41:1.
99. Monnier P, Savary M, Fontolliet C, Ollyo JB. Photodetection and photodynamic therapy of early squamous cell carcinomas of the pharynx, oesophagus and tracheo-bronchial tree. Lasers Med Sci 1990;5:149-68.
100. Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, et al. Photosensitization and photodynamic therapy of oesophageal, duodenal and colorectal tumours using 5-aminolevulinic acid-induced protoporphyrin. IX. A pilot study. Gut 1995;36:67-75.
101. Overholt BF, Panjehpour M. Barrett's oesophagus: PDT for abalation of dysplasia, reduction of specialised mucosa and treatment of superficial oesophageal cancer. Gastrointest Endosc 1995;42:64-70.
102. Laukka MA, Wang KK. Initial results using low-dose photodynamic therapy in the treatment of Barrett's oesophagus. Gastrointest Endosc 1995;42:59-63.
103. Gossner L, Hahn C. Oral administration of 5-aminolevulinic acid for photodynamic therapy in patients with gastrointestinal carcinomas; preliminary results. Gastroenterology 1994;106: A387.
104. Loh CS, MacRobert AJ, Bedwell J, Regula J, Krasner N, Bown SG. Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. Br J Cancer 1993;68:41-51.
105. McCaughan JS, Hawley PC, Walker J. Management of endobronchial tumours: a comparative study. Semin Surg Oncol 1989;5:38-47.
106. Valduga G, Nonell S, Reddi E, Jori G, Braslavsky SE. The production of singlet molecular oxygen by zinc (II)-phthalocyanine in ethanol and in unilamellar vesicles. Chemical quenching and phosphorescence studies. Photochem Photobiol 1988;48:1-5.
107. Gossner L, Sroka R, May A, Rick K, Hahn EG, Ell C. Photodynamic abalation of severe dysplasia and mucosal cancer in Barrett's oesophagus using 5-ALA. Gastroenterology 1997;112:A570.
108. Overholt BF, Panjehpour M. Photodynamic therapy destroys dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc 1996;43:205.
109. Verspaget HW, Torremans PAJ, Van Lerssel AJHM, Lamers CBHW, Dubbelman TMAR, Griffioen G. Photodynamic therapy affects spontaneous and NK cell mediated tumour cell lysis. Gastroenterology 1997;112:A674.
110. Zoepf T, Preclik G, Boeck W, et al. Photodynamic therapy with 5-ALA for the treatment of dysplasia and early carcinoma in the upper GI-tract. Gastroenterology 1998;114:G2936.
111. Nourbakhsh A, Wang KK, Wang LM, Swanson N, Pittelkow MR. Susceptibility of Barrett's and squamous epithelium cells to photodynamic therapy. Gastroenterology 1997;112:A629.
112. Gossner L, May A, Sroka R, Rabenstein T, Scheider TH, Hahn EG. Photodynamic therapy of Barrett's oesophagus with high grade dysplasia and early cancer. Gastroenterology 1998;114: G0558.
113. Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, et al. Photodynamic abalation of high grade dysplasia and early cancer in Barrett's oesophagus by means of 5-aminolevulinic acid. Gastroenterology 1998;114:448-55.
114. Overholt BF, Panjehpour M. Photodynamic therapy eliminates dysplasia in Barrett's oesophagus. Gastroenterology 1997;112: A634.
115. Overholt BF, Panjehpour M. Photodynamic therapy for Barrett's esophagus: clinical update. Am J Gastroenterol 1996; 91:9.
116. Gore S, Healy CJ, Sutton R, Eyre-Brook IA, Gear MW, Shepherd NA, et al. Regression of columnar lined (Barrett's) oesophagus with continuous with omeprazole therapy. Aliment Pharmcol Ther 1993;7:623-8.
117. Wang KK, Gutta K, Laukka MA. A prospective randomised trial of low dose PDT in the treatment of Barrett's oesophagus. Gastroenterology 1994;106:A 208.
118. Wang KK, Song LM, Nourbakhsh A, Laukka M, Gutta K, Geller A, et al. Controlled trial of low dose photodynamic therapy for Barrett's oesophagus. Gastroenterology 1997;112: A676.
119. Wang KK, Wongkeesong M, Nijhawan P, Nourbakhsh A, Balm R. Does non-dysplastic Barrett's epithelium respond better to mucosal ablation? Gastroenterology 1998;114:G2894.
120. Berenson MM, Johnson TD, Markowitz NR, Buchi KN, Samowitz WS. Restoration of squamous mucosa after ablation of Barrett's oesophageal epithelium. Gastroenterology 1993; 104:1686-91.
121. Schnell TG, Sontag SJ, Chejfec G. Adenocarcinoma arising in tongues or short segments of Barrett's oesophagus. Dig Dis Sci 1992;37:137-43.
122. Biddleston LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA. The histopathology of treated Barrett's oesophagus-squamous re-epithelialisation after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998;22:239-45.
123. Reid BJ. Barrett's oesophagus and oesophageal adenocarcinoma. Gastroenterol Clin North Am 1991;20:817-34.
124. Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high grade dysplasia in Barrett's oesophagus. Am J Gastroenterol 1993;88:1832-6.
125. Overholt BF, Panjehpour M, De Novo RC, Peterson MG. Photodynamic therapy for esophageal cancer using a 180° windowed esophageal balloon. Lasers Surg Med 1994;14:27-33.
126. Panjehpour M, Overholt BF, Denovo R, Sneed R, Peterson M. Centering balloon to improve oesophageal PDT. Laser Surg Med 1992;12:631-8.
127. Overholt BF, Panjehpour M, Denovo R, Peterson M. A centering balloon for PDT for oesophageal cancer tested in a canine model. Gastrointest Endosc 1993;39:782-7.
128. Puolakkainen P, Schroder T. Photodynamic therapy of gastrointestinal tumours: a review. Dig Dis 1992;10:53-60.
129. Cohen S, Margalit R. Binding of porphyrin to human serum albumin. Structure-activity relationships. Biochem J 1990;270: 325-30.
130. Wong LM, Wang KK, Nourbakhsh A, Swanson N, Pittelkow MR. A new method of photosensitizer administration in photodynamic therapy. Gastroenterology 1997;112:A683.
131. Amano T, Prout G, Lin CW. Intra-tumour injection as a more effective means of porphyrin administration for photodynamic therapy. J Urol 1988;139:392-5.
132. Heier SK, Heier LM, Bellnier D, Khan F, Gronowitz SD, Willner I, et al. A pharmacokinetic basis for changing parameters of photodynamic therapy for Barrett's - addressing photosensitivity and patient convenience. Gastroenterology 1997;112:A98.
133. Ortner M, Zumbusch K, Liebertruth J, Ernst H, Weber J, Wirth J, et al. Photodynamic therapy of Barrett's oesophagus after local administration of 5 amino laevulinic acid. Gastroenterology 1997;112:A633.